| Normal (n = 187) | Sarcopenia (n = 171) | Obesity (n = 275) | Sarcopenic obesity (n = 83) | p value* |
---|---|---|---|---|---|
Insulin (%) | 34 | 39 | 36 | 39 | 0.756 |
Sulfonylureas (%) | 20 | 21 | 24 | 21 | 0.652 |
Metformins (%) | 24 | 15 | 43 | 29 | < 0.001 |
Alpha-GIs (%) | 16 | 16 | 10 | 12 | 0.146 |
Glinides (%) | 5 | 4 | 3 | 5 | 0.704 |
TZDs (%) | 9 | 3 | 8 | 5 | 0.068 |
DPP4 inhibitors (%) | 27 | 30 | 39 | 46 | 0.005 |
SGLT2 inhibitors (%) | 1 | 0 | 1 | 1 | 0.631 |
GLP1-RAs (%) | 2 | 2 | 4 | 1 | 0.581 |
ACEIs (%) | 5 | 2 | 3 | 5 | 0.396 |
ARBs (%) | 41 | 32 | 56 | 50 | < 0.001 |
CCBs (%) | 32 | 28 | 46 | 43 | < 0.001 |
Alpha blockers (%) | 1 | 1 | 3 | 0 | 0.122 |
Beta blockers (%) | 11 | 8 | 11 | 18 | 0.129 |
Diuretics (%) | 10 | 10 | 8 | 12 | 0.790 |
Statins (%) | 47 | 31 | 54 | 40 | < 0.001 |
Fibrates (%) | 5 | 2 | 2 | 2 | 0.103 |
Ezetimib (%) | 5 | 2 | 2 | 0 | 0.082 |
EPAs (%) | 3 | 2 | 3 | 5 | 0.774 |
UA lowering agents (%) | 8 | 8 | 15 | 13 | 0.029 |
Anti-platelet agents (%) | 18 | 22 | 26 | 33 | 0.050 |